Status:
COMPLETED
Post-Poliosyndrome Treated With Intravenous Immunoglobulin (IvIg)
Lead Sponsor:
Haukeland University Hospital
Conditions:
Post-Polio Syndrome
Eligibility:
All Genders
Up to 75 years
Phase:
PHASE2
PHASE3
Brief Summary
Inflammatory cytokines in the cerebrospinal fluid may contribute to the new muscle weakness, fatigue and pain experienced by patients with post-polio syndrome. Intravenousimmunoglobulin (IvIg) reduces...
Detailed Description
Post-polio syndrome (PPS) is characterised by new muscle weakness, pain, and fatigue several years after the attack of acute polio. This leads to increased disability, and up to now only supportive th...
Eligibility Criteria
Inclusion
- Post-polio syndrome diagnosed at Dept of Neurology, Haukeland University Hospital Walking ability -
Exclusion
- Other autoimmune disorders Other ongoing autoimmune therapy Severe cardiopulmonary disease IgA deficiency Previous treatment of IvIg Wheelchair dependence
Key Trial Info
Start Date :
August 1 2003
Trial Type :
INTERVENTIONAL
End Date :
July 1 2004
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00231439
Start Date
August 1 2003
End Date
July 1 2004
Last Update
December 13 2005
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.